Peripheral Blood Lipidomic and Ceramide Profiles in Atrial Fibrillation (LIPID-AF)
7 agosto 2026 aggiornato da: She JianQing, First Affiliated Hospital Xi'an Jiaotong University
Association of Peripheral Blood Lipidomic and Ceramide Profiles With Atrial Fibrillation: A Prospective Multi-Cohort Observational Study
This prospective multi-cohort observational study evaluates the association between peripheral blood lipidomic and ceramide profiles and atrial fibrillation.
The study hypothesis is that peripheral blood lipidomic features and ceramide-related profiles are associated with the presence of atrial fibrillation.
Participants with atrial fibrillation and control participants with other cardiovascular diseases will be prospectively enrolled.
Peripheral blood samples will be analyzed using untargeted lipidomic profiling in one cohort and targeted ceramide assays in another cohort.
Panoramica dello studio
Stato
Reclutamento
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Atrial fibrillation is a common cardiac arrhythmia associated with metabolic disturbance and cardiac remodeling. Lipid metabolism, including sphingolipid and ceramide metabolism, may be involved in the pathophysiology of atrial fibrillation. Further clinical evidence is needed to clarify whether peripheral blood lipidomic and ceramide profiles are associated with atrial fibrillation.
This study is designed as a prospective multi-cohort observational study. Participants will be classified into an atrial fibrillation group or a control group according to Holter monitoring and clinical information. Control participants will be patients with other cardiovascular diseases without documented atrial fibrillation. Peripheral blood samples will be collected for lipidomic or targeted ceramide analysis.
Untargeted lipidomic profiling will be used to evaluate peripheral blood lipidomic features in one cohort, and targeted ceramide assays will be used to evaluate peripheral blood ceramide profiles in another cohort. The overall purpose of this study is to explore the relationship between peripheral blood lipidomic and ceramide profiles and atrial fibrillation.
Tipo di studio
Osservativo
Iscrizione (Stimato)
200
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Weiyan Zhang
- Numero di telefono: 0086-13571200428
- Email: zwhy19324@gmail.com
Backup dei contatti dello studio
- Nome: Weiyan Zhang
- Numero di telefono: 0086-13571200428
- Email: 3093887704@qq.com
Luoghi di studio
-
-
Shaanxi
-
Xi'an, Shaanxi, Cina, 710061
- Reclutamento
- First Affiliated Hospital of Xian JiaotongUniversity
-
Contatto:
- Weiyan Zhang
- Numero di telefono: 0086-13571200428
- Email: zwhy19324@gmail.com
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Metodo di campionamento
Campione non probabilistico
Popolazione di studio
The study population includes adult patients prospectively enrolled from clinical cardiovascular cohorts.
Participants will include patients with atrial fibrillation diagnosed by Holter monitoring and control patients with other cardiovascular diseases without documented atrial fibrillation.
All participants will provide peripheral blood samples for untargeted lipidomic profiling or targeted ceramide analysis.
Descrizione
Inclusion Criteria:
- Adults aged 18 years or older.
- Participants who are able to provide informed consent.
- Participants diagnosed with atrial fibrillation based on Holter monitoring, or control participants with other cardiovascular diseases and no documented atrial fibrillation.
- Participants with available peripheral blood samples for untargeted lipidomic profiling or targeted ceramide analysis.
Exclusion Criteria:
- Inability or unwillingness to provide informed consent.
- Missing key clinical information.
- Missing or poor-quality peripheral blood samples unsuitable for lipidomic or targeted ceramide analysis.
- Participants considered unsuitable for this study by the investigators.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Cohort 1 Atrial Fibrillation Group
Participants in cohort 1 diagnosed with atrial fibrillation based on Holter monitoring.
Peripheral blood samples will be analyzed using untargeted lipidomic profiling.
|
Peripheral blood samples from cohort 1 will be analyzed using untargeted lipidomic profiling.
No treatment or therapeutic intervention will be assigned by the investigators.
|
|
Cohort 1 Control Group
Control participants in cohort 1 with other cardiovascular diseases and no documented atrial fibrillation.
Peripheral blood samples will be analyzed using untargeted lipidomic profiling.
|
Peripheral blood samples from cohort 1 will be analyzed using untargeted lipidomic profiling.
No treatment or therapeutic intervention will be assigned by the investigators.
|
|
Cohort 2 Atrial Fibrillation Group
Participants in cohort 2 diagnosed with atrial fibrillation based on Holter monitoring.
Peripheral blood samples will be analyzed using targeted ceramide assays.
|
Peripheral blood samples from cohort 2 will be analyzed using targeted ceramide assays.
No treatment or therapeutic intervention will be assigned by the investigators.
|
|
Cohort 2 Control Group
Control participants in cohort 2 with other cardiovascular diseases and no documented atrial fibrillation.
Peripheral blood samples will be analyzed using targeted ceramide assays.
|
Peripheral blood samples from cohort 2 will be analyzed using targeted ceramide assays.
No treatment or therapeutic intervention will be assigned by the investigators.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Peripheral Serum Concentration of Cer(d18:1/18:1), nmol/L
Lasso di tempo: Baseline
|
The concentration of Cer(d18:1/18:1) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L.
Concentrations will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Peripheral Serum Concentration of Cer(d18:1/16:0), nmol/L
Lasso di tempo: baseline
|
The concentration of Cer(d18:1/16:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L.
Concentrations will be compared between participants with atrial fibrillation and control participants.
|
baseline
|
|
Peripheral Serum Concentration of Cer(d18:1/18:0), nmol/L
Lasso di tempo: Baseline
|
The concentration of Cer(d18:1/18:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L.
Concentrations will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Peripheral Serum Concentration of Cer(d18:1/20:0), nmol/L
Lasso di tempo: Baseline
|
The concentration of Cer(d18:1/20:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L.
Concentrations will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Peripheral Serum Concentration of Cer(d18:1/22:0), nmol/L
Lasso di tempo: Baseline
|
The concentration of Cer(d18:1/22:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L.
Concentrations will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Peripheral Serum Concentration of Cer(d18:1/24:0), nmol/L
Lasso di tempo: Baseline
|
The concentration of Cer(d18:1/24:0) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L.
Concentrations will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Peripheral Serum Concentration of Cer(d18:1/24:1), nmol/L
Lasso di tempo: Baseline
|
The concentration of Cer(d18:1/24:1) in peripheral serum will be quantified using a targeted mass spectrometry-based assay and reported in nmol/L.
Concentrations will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Normalized Relative Abundance of Serum Cer(d18:1/18:1), AU
Lasso di tempo: Baseline
|
The normalized relative abundance of Cer(d18:1/18:1) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU).
Relative abundance will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Normalized Relative Abundance of Serum Cer(d18:1/16:0), AU
Lasso di tempo: Baseline
|
The normalized relative abundance of Cer(d18:1/16:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU).
Relative abundance will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Normalized Relative Abundance of Serum Cer(d18:1/18:0), AU
Lasso di tempo: Baseline
|
The normalized relative abundance of Cer(d18:1/18:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU).
Relative abundance will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Normalized Relative Abundance of Serum Cer(d18:1/20:0), AU
Lasso di tempo: Baseline
|
The normalized relative abundance of Cer(d18:1/20:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU).
Relative abundance will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Normalized Relative Abundance of Serum Cer(d18:1/22:0), AU
Lasso di tempo: Baseline
|
The normalized relative abundance of Cer(d18:1/22:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU).
Relative abundance will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Normalized Relative Abundance of Serum Cer(d18:1/24:0), AU
Lasso di tempo: Baseline
|
The normalized relative abundance of Cer(d18:1/24:0) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU).
Relative abundance will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
|
Normalized Relative Abundance of Serum Cer(d18:1/24:1), AU
Lasso di tempo: Baseline
|
The normalized relative abundance of Cer(d18:1/24:1) in peripheral serum will be measured using an untargeted mass spectrometry-based lipidomics platform and reported in arbitrary units (AU).
Relative abundance will be compared between participants with atrial fibrillation and control participants.
|
Baseline
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
15 giugno 2017
Completamento primario (Stimato)
1 gennaio 2027
Completamento dello studio (Stimato)
1 febbraio 2027
Date di iscrizione allo studio
Primo inviato
4 luglio 2026
Primo inviato che soddisfa i criteri di controllo qualità
7 agosto 2026
Primo Inserito (Effettivo)
11 agosto 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
11 agosto 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
7 agosto 2026
Ultimo verificato
1 agosto 2026
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- XJTU1AF-CRF-2018-025
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
NO
Descrizione del piano IPD
Individual participant data will not be shared because the study involves clinical information and biological sample-related data.
Data sharing is not planned beyond the approved study protocol and ethical approval.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .